{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:24:34Z","timestamp":1786944274544,"version":"build-2736575974"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Urol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Salvage radiotherapy (SRT) is one of the treatment options after progression following surgical management, with effectiveness varying according to patient risk and clinical-pathological characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the effectiveness of SRT alone versus SRT combined with androgen deprivation therapy (ADT) in men with biochemical recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review with advanced searches in MEDLINE (PubMed), EMBASE, SCOPUS, Cochrane CENTRAL, and LILACS for the period 1990\u20132024. Two independent reviewers performed study selection (titles\/abstracts and full text) and data extraction. Risk of bias was assessed with ROBINS-I and RoB 2.0.\u00a0A random-effects meta-analysis was used to pool effect estimates. PROSPERO registration: CRD42025640604.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirteen studies were included. Nine reported overall survival (OS) and biochemical progression-free survival (b-PFS) respectively, four clinical progression-free survival (c-PFS), and eight metastasis-free survival (MFS). Combined SRT+ADT was associated with improved b-PFS (HR 0.51; 95% CI 0.45-0.57; I\u00b2=0%) and MFS (HR 0.71; 95% CI 0.60-0.84; I\u00b2=39%), whereas the remaining meta-analyzed outcomes showed no consistent benefit or were limited by heterogeneity. Regarding toxicity, the most frequent adverse events were endocrine and sexual, related to hormonal blockade, gynecomastia and erectile dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Combined SRT + ADT improves biochemical disease control and may reduce the risk of metastasis in selected patients with biochemical recurrence after radical postatectomy, whereas the effect on overall survival remains uncertain. Individualized management requires risk stratification when deciding on the addition and duration of ADT to optimize oncologic outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/<\/jats:ext-link>\n                      , identifier CRD42025640604.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fruro.2026.1836469","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:33:46Z","timestamp":1786941226000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of androgen suppression therapy at salvage radiotherapy in recurrent prostate cancer: a systematic review with meta-analysis"],"prefix":"10.3389","volume":"6","author":[{"given":"Maria Juliana","family":"Chaves Medina","sequence":"first","affiliation":[{"name":"Urology Research and Innovation Group, Faculty of Medicine, Universidad Nacional de Colombia","place":["Bogot\u00e1, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Varela Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Urology Research and Innovation Group, Faculty of Medicine, Universidad Nacional de Colombia","place":["Bogot\u00e1, Colombia"]},{"name":"Hospital Universitario Nacional de Colombia","place":["Bogot\u00e1, Colombia"]},{"name":"Urology Unit, Instituto Nacional de Cancerolog\u00eda","place":["Bogot\u00e1, Colombia"]},{"name":"Urology Unit, Department of Surgery, Faculty of Medicine, Universidad Nacional de Colombia","place":["Bogot\u00e1, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfredo","family":"Donoso Donoso","sequence":"additional","affiliation":[{"name":"Urology Research and Innovation Group, Faculty of Medicine, Universidad Nacional de Colombia","place":["Bogot\u00e1, Colombia"]},{"name":"Urology Unit, Department of Surgery, Faculty of Medicine, Universidad Nacional de Colombia","place":["Bogot\u00e1, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Moreno-Chaparro","sequence":"additional","affiliation":[{"name":"Hospital Universitario Nacional de Colombia","place":["Bogot\u00e1, Colombia"]},{"name":"Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Universidad Nacional de Colombia","place":["Bogot\u00e1, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Eslava-Schmalbach","sequence":"additional","affiliation":[{"name":"Hospital Universitario Nacional de Colombia","place":["Bogot\u00e1, Colombia"]},{"name":"Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Universidad Nacional de Colombia","place":["Bogot\u00e1, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur Urol"},{"key":"B2","unstructured":"Cancer Today"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.04.034","article-title":"Risk stratification of patients with recurrence after primary treatment for prostate cancer: a systematic review","volume":"86","author":"Weiner","year":"2024","journal-title":"Eur Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/MOLECULES27175730","article-title":"Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches","volume":"27","author":"Sekhoacha","year":"2022","journal-title":"Molecules"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/S00432-012-1309-9","article-title":"Adjuvant and salvage radiotherapy after prostatectomy: outcome analysis of 307 patients with prostate cancer","volume":"139","author":"Detti","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/J.EURURO.2017.01.039","article-title":"Adjuvant and salvage radiotherapy after radical prostatectomy in prostate cancer patients","volume":"72","author":"Gandaglia","year":"2017","journal-title":"Eur Urol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/JAMAONCOL.2020.0109","article-title":"Association of presalvage radiotherapy PSA levels after prostatectomy with outcomes of long-term antiandrogen therapy in men with prostate cancer","volume":"6","author":"Dess","year":"2020","journal-title":"JAMA Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000481438","article-title":"Management of biochemical recurrence after primary curative treatment for prostate cancer: a review","volume":"100","author":"Artibani","year":"2018","journal-title":"Urol Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.010","article-title":"Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047)","volume":"35","author":"Parker","year":"2024","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.06.027","article-title":"A systematic review and framework for the use of hormone therapy with salvage radiation therapy for recurrent prostate cancer","volume":"73","author":"Spratt","year":"2018","journal-title":"Eur Urol"},{"key":"B12","unstructured":"Edn. Presented at the EAU Annual Congress Madrid 2025. ISBN 978-94-92671-29-5"},{"key":"B13","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions | Cochrane"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PMED.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PloS Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.I4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.L4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/XEB.0000000000000065","article-title":"Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness","volume":"13","author":"Tufanaru","year":"2015","journal-title":"Int J Evid Based Healthc"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/BMJEBM-2020-111493","article-title":"Framework for the synthesis of non-randomised studies and randomised controlled trials: a guidance on conducting a systematic review and meta-analysis for healthcare decision making","volume":"27","author":"Sarri","year":"2022","journal-title":"BMJ Evid Based Med"},{"key":"B19","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions | Cochrane"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.N71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30486-3","article-title":"Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial","volume":"20","author":"Carrie","year":"2019","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.11.023","article-title":"Salvage radiotherapy versus hormone therapy for prostate-specific antigen failure after radical prostatectomy: a randomised, multicentre, open-label, phase 3 trial (JCOG0401)\u2020[Formula presented","volume":"77","author":"Yokomizo","year":"2020","journal-title":"Eur Urol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/CURRONCOL30080526","article-title":"Salvage whole-pelvic radiation and long-term androgen-deprivation therapy in the management of high-risk prostate cancer: long-term update of the McGill 0913 study","volume":"30","author":"Elakshar","year":"2023","journal-title":"Curr Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00549-X","article-title":"Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial","volume":"403","author":"Parker","year":"2024","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00548-8","article-title":"Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial","volume":"403","author":"Parker","year":"2024","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0123-9015(12)70011-2","article-title":"Radioterapia de salvamento para pacientes con c\u00e1ncer de pr\u00f3stata: experiencia en el Instituto Nacional de Cancerolog\u00eda","volume":"16","author":"Ospino","year":"2012","journal-title":"Rev Colombiana Cancerolog\u00eda"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3892\/IJO.2012.1694","article-title":"Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy","volume":"42","author":"Cort\u00e9s-Gonz\u00e1lez","year":"2013","journal-title":"Int J Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3109\/0284186X.2015.1088170","article-title":"Salvage radiation therapy following radical prostatectomy. A national Danish study","volume":"55","author":"Ervandian","year":"2016","journal-title":"Acta Oncol (Madr)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.9647","article-title":"Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy","volume":"34","author":"Tendulkar","year":"2016","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1159\/000481265","article-title":"Combination of androgen deprivation therapy and salvage radiotherapy versus salvage radiotherapy alone for recurrent prostate cancer after radical prostatectomy","volume":"99","author":"Yoo","year":"2017","journal-title":"Urol Int"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/J.EURURO.2019.02.004","article-title":"Assessing the role and optimal duration of hormonal treatment in association with salvage radiation therapy after radical prostatectomy: results from a multi-institutional study","volume":"76","author":"Fossati","year":"2019","journal-title":"Eur Urol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/J.ACURO.2014.03.005","article-title":"Influential factors in the response to salvage radiotherapy after radical prostatectomy","volume":"38","author":"Algarra","year":"2014","journal-title":"Actas Urol Esp"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.05.012","article-title":"Contemporary evaluation of salvage radiotherapy for prostate cancer: radiotherapy dose, field size, and use of hormone therapy","volume":"84","author":"Jiang","year":"2023","journal-title":"Eur Urol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.eururo.2017.01.039","article-title":"Adjuvant and salvage radiotherapy after radical prostatectomy in prostate cancer patients[Figure presented","volume":"72","author":"Gandaglia","year":"2017","journal-title":"Eur Urol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.5306\/WJCO.V11.I1.1","article-title":"Are all prostate cancer patients \u201cfit\u201d for salvage radiotherapy","volume":"11","author":"Segundo","year":"2020","journal-title":"World J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003891","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part II: treatment delivery for non-metastatic biochemical recurrence after primary radical prostatectomy","volume":"211","author":"Morgan","year":"2024","journal-title":"J Urol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1590\/S1677-55382006000400006","article-title":"Salvage conformal radiotherapy for biochemical recurrent prostate cancer after radical prostatectomy","volume":"32","author":"Monti","year":"2006","journal-title":"Int Braz J Urol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/J.EURURO.2025.05.013","article-title":"Duration of androgen suppression with postoperative radiotherapy (DADSPORT) for nonmetastatic prostate cancer: a collaborative systematic review and meta-analysis of aggregate data","volume":"88","author":"Burdett","year":"2025","journal-title":"Eur Urol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/J.1464-410X.2009.09136.X","article-title":"Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation","volume":"106","author":"Song","year":"2010","journal-title":"BJU Int"},{"key":"B42","unstructured":"Prostate Cancer - Uroweb"}],"container-title":["Frontiers in Urology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2026.1836469\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:33:52Z","timestamp":1786941232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2026.1836469\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":42,"alternative-id":["10.3389\/fruro.2026.1836469"],"URL":"https:\/\/doi.org\/10.3389\/fruro.2026.1836469","relation":{},"ISSN":["2673-9828"],"issn-type":[{"value":"2673-9828","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"article-number":"1836469"}}